title: Dexamethasone pretreatment attenuates lung and kidney injury in cholestatic rats induced by hepatic ischemia/reperfusion.
abstract: Hepatic ischemia followed by reperfusion (IR) results in mild to severe organ injury, in which tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) seem to be involved. Thus, we aim to assess the influence of hepatic ischemia/reperfusion injury on remote organs in addition to cholestasis and consider the possible efficacy of steroid pretreatment in reducing the injury. A common bile duct ligation model was done on 24 male Sprague-Dawley rats. After 7 days, the rats were divided randomly into control group, IR group, and dexamethasone (DEX) group. The IR group showed significant increases in serum alanine aminotransferase, aspartate aminotransferase, and creatinine levels compared with the control and DEX groups. By ELISA techniques, higher levels of TNF-α and IL-1β in lung and kidney tissues were measured in the IR group than in the control and DEX groups, these were verified by immunohistochemistry. The lung histology of the IR group rats showed neutrophil infiltration, interstitial edema, and alveolar wall thickening. Kidney histology of the IR group rats showed vacuolization of the proximal tubular epithelial cells and tubular dilatation with granular eosinophilic casts. Better morphological aspects were observed in the DEX-pretreated animals. Minimal lesions were observed in the control. The results suggest that hepatic ischemia/reperfusion injury in cholestatic rats induced lung and kidney injuries. Pretreatment with dexamethasone reduced the IR-induced injury in addition to cholestasis.
authors.affiliation: Union Hospital, Fujian Medical University, Fuzhou, Fujian, China.
authors.forename: Liangyi
authors.initials: L
authors.lastname: Zhou
authors.forename: Xiangqing
authors.initials: X
authors.lastname: Yao
authors.forename: Yanling
authors.initials: Y
authors.lastname: Chen
mesh_terms: D058186:Acute Kidney Injury / Q000188:drug therapy* / Q000209:etiology; D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D002779:Cholestasis / Q000188:drug therapy* / Q000209:etiology; D003404:Creatinine / Q000097:blood; D003907:Dexamethasone / Q000627:therapeutic use*; D004487:Edema; D053583:Interleukin-1beta / Q000502:physiology; D007668:Kidney / Q000473:pathology; D007687:Kidney Tubules, Proximal / Q000473:pathology; D008099:Liver / Q000098:blood supply / Q000473:pathology; D008168:Lung / Q000378:metabolism / Q000473:pathology; D008297:Male; D020556:Neutrophil Infiltration; D011650:Pulmonary Alveoli / Q000473:pathology; D011654:Pulmonary Edema; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000150:complications* / Q000378:metabolism / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology
chemical_list: D053583:Interleukin-1beta; D014409:Tumor Necrosis Factor-alpha; D003907:Dexamethasone; D003404:Creatinine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase